GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Sarepta Therapeutics Inc (SRPT) [hlAlert]

Rating:
Neutral SRPT

Sarepta Therapeutics Inc (SRPT) downgraded to Neutral with price target $21 by Robert W. Baird

Posted on: Tuesday,  Oct 28, 2014  8:25 AM ET by Robert W. Baird

Robert W. Baird rated Neutral Sarepta Therapeutics Inc (NASDAQ: SRPT) on 10/28/2014. Previously Robert W. Baird rated Outperform
Sarepta Therapeutics Inc (NASDAQ: SRPT) on 04/04/2013., when the stock price was $35.82. Since then, Sarepta Therapeutics Inc has lost 55.72% of its value until Robert W. Baird rated SRPT Outperform on 10/28/2014, when the price was $15.86. .

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/6/2015 8:25 AM Buy
None
14.32 20.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/28/2014 8:25 AM Hold
None
15.86 21.00
4/4/2013 8:25 AM Buy
None
35.82 63.00
4/3/2013 5:25 PM Buy
None
63.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy